TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02358824
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)~(1arm:1period and 3period, 2arm: 2period and 4period)
Study: NCT02358824
Drug: S-amlodipine
Normalized name: S-amlodipine
DrugBank: Levamlodipine (DB09237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)~(1arm:1period and 3period, 2arm: 2period and 4period)
Study: NCT00965848
Drug: Doripenem
Normalized name: Doripenem
DrugBank: Doripenem (DB06211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
Study: NCT03646344
Drug: Heme Arginate 25 MG/ML
Normalized name: heme arginate 25 MG/ML
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
Study: NCT03646344
Drug: 0.9% Sodium-chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
Study: NCT04231435
Drug: Fedratinib
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral
Study: NCT04231435
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT04231435
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral
Study: NCT00006019
Drug: azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00006019
Drug: sodium phenylbutyrate
Normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00396734
Drug: Provigil (Modafinil)
Normalized name: modafinil Oral Tablet [Provigil]
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increase from 100mg to 400mg during 1 month of treatment
Study: NCT00396734
Drug: Topamax (Topiramate)
Normalized name: topiramate Oral Tablet [Topamax]
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increase from 25mg to 200mg in one month (double every week)
Study: NCT04150575
Drug: HLX10+Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
Study: NCT03403634
Drug: Rintatolimod
Normalized name: Rintatolimod
DrugBank: Rintatolimod (DB16425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01997775
Drug: METFORMIN
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 \> 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
Study: NCT03058406
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
Study: NCT04018872
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of itraconazole twice daily from completion of neoadjuvant chemoradiation until esophagectomy.
Study: NCT02877485
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 sprays sprayed to both nostrils daily for 42 days.
Study: NCT01181895
Drug: Vilanterol
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilanterol inhalation powder inhaled orally once daily for 12 weeks
Study: NCT01181895
Drug: Salmeterol Inhalation Powder
Normalized name: Salmeterol Inhalation Powder
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
Study: NCT00821691
Drug: Amantadin
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadin caps
Study: NCT02120339
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02177344
Drug: Low dose of Ipratropium bromide
Normalized name: ipratropium bromide Metered Dose Inhaler
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One puff, 4 times daily by oral inhalation
Study: NCT02177344
Drug: High dose of Ipratropium bromide
Normalized name: ipratropium bromide Metered Dose Inhaler
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One puff, 4 times daily by oral inhalation
Study: NCT02177344
Drug: Atrovent
Normalized name: Atrovent
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two puffs, 4 times daily by oral inhalation
Study: NCT03319043
Drug: Chanqin granules
Normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
Study: NCT00452504
Drug: SRA-444
Normalized name: SRA-737
DrugBank: SRA-737 (DB16876)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01363323
Drug: Methylnaltrexone (MNTX)
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose 1
Study: NCT01363323
Drug: Methylnaltrexone (MNTX)
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose 2
Study: NCT01363323
Drug: Methylnaltrexone (MNTX)
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose 3
Study: NCT01363323
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02066298
Drug: Mometasone 220mcg BID
Normalized name: mometasone
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone is an ICS
Study: NCT02066298
Drug: Tiotropium Respimat 5mcg QD
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium is a LMA
Study: NCT05095480
Drug: Red Yeast Rice Pill
Normalized name: red yeast rice Pill
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking Lesstat
Study: NCT02294292
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.
Study: NCT02294292
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction
Study: NCT01519518
Drug: unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 units/kg body weight intravenous
Study: NCT01519518
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
Study: NCT00013897
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00013897
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00013897
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01169857
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
Study: NCT03129347
Drug: Nalmefene
Normalized name: Nalmefene
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene
Study: NCT02934139
Drug: Cavosonstat
Normalized name: Cavosonstat
DrugBank: Cavosonstat (DB14775)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFTR modulator that stabilizes CFTR
Study: NCT01679119
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine 1.4mg/m2(max 2mg)IV given day 1
Study: NCT01679119
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375mg/m2 IV given day 1
Study: NCT01679119
Drug: Inotuzumab Ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
Study: NCT01679119
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
Study: NCT01629082
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01629082
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02564198
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT00982319
Drug: Broccoli sprout extract
Normalized name: broccoli sprout extract
DrugBank: Broccoli (DB10511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µmols of sulforaphane (dissolvable)
Study: NCT00982319
Drug: Mango juice
Normalized name: mango juice
DrugBank: Mango (DB10657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mL of mango juice
Study: NCT01922596
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00030550
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00151801
Drug: interferon-beta 1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03788889
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine infusion
Study: NCT03788889
Drug: Phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital intravenous injection
Study: NCT03788889
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT01050595
Drug: Methylnaltrexone Bromide
Normalized name: Methylnaltrexone Bromide
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance \<30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
Study: NCT01050595
Drug: Placebo-Normal Saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
Study: NCT02698501
Drug: MEDI9929
Normalized name: MEDI9929
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
Study: NCT00723801
Drug: Atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 50mg PO QD
Study: NCT00723801
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 100mg PO QD
Study: NCT03348904
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
Study: NCT03348904
Drug: Epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat administered orally at the protocol-defined dose twice daily.
Study: NCT03348904
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Study: NCT03348904
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Study: NCT03348904
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Study: NCT03348904
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Study: NCT03348904
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
Study: NCT00097591
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT00097591
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally
Study: NCT03003676
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD1 blockade
Study: NCT03732638
Drug: Rimegepant
Normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rimegepant 75 mg tablet EOD
Study: NCT00259753
Drug: Bevasiranib
Normalized name: Bevasiranib
DrugBank: Bevasiranib (DB06642)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00786916
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
Study: NCT00786916
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
Study: NCT00204191
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00753324
Drug: Routine three-drug antiretroviral prophylaxis
Normalized name: three-lobe sage extract
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
Study: NCT00058890
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
Study: NCT01332305
Drug: GEn (XP13512/GSK1838262)
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
Study: NCT00572572
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
Study: NCT01185847
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard treatment, up to 6 cycles
Study: NCT01185847
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard treatment, up to 6 cycles
Study: NCT01185847
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: standard treatment, up to 6 cycles
Study: NCT03424746
Drug: disodium EDTA
Normalized name: Disodium EDTA
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label study of TACT-formula, EDTA-based chelation therapy + commercially available TACT oral multi vitamins, delivering 40-50 infusions over 1 year.
Study: NCT01958918
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5 mg intravitreal injection
Study: NCT01958918
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg intravitreal injection
Study: NCT00668460
Drug: Lactic acid (Dermacid)
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04327934
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist up to 16 days.
Study: NCT00962429
Drug: lipoic acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
Study: NCT03713619
Drug: secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab 300mg every 2 or every 4 weeks
Study: NCT00351975
Drug: Belinostat
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00351975
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT01369290
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
Study: NCT01369290
Drug: bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
Study: NCT01369290
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.